A Double-Blind, Placebo-Controlled Trial of Sibutramine for Olanzapine-Associated Weight Gain

Henderson, David C.; Copeland, Paul M.; Daley, Tara B.; Borba, Christina P.C.; Cather, Corrine; Nguyen, Dana; Louie, Pearl M.; Evins, A. Eden; Freudenreich, Oliver; Hayden, Doug; Goff, Donald C.

doi:10.1176/appi.ajp.162.5.954

Cited by 116 publications

(120 citation statements)

References 36 publications

Supporting

Mentioning

112

Contrasting

Unclassified

Order By: Relevance

“…Although the negative public health implications of the weight gain and other metabolic adverse effects of olanzapine have become a matter of concern to both the psychiatry and endocrinology communities (American Diabetes Association, 2004), olanzapine continues to be widely prescribed. Approaches to reducing atypical-induced weight gain in schizophrenia using diet, exercise, and appetite suppressant drugs have demonstrated some short-term benefits (Henderson et al, 2005;Graham et al, 2005a, b). However, long-term efficacy of such approaches to maintaining weight reduction is unlikely given disappointing results of such approaches to long-term weight reduction in the general population (Glazer, 2001).…”

Section: Introductionmentioning

confidence: 99%

Olanzapine-Induced Weight Gain and Increased Visceral Adiposity is Blocked by Melatonin Replacement Therapy in Rats

Raskind

Burke

Crites

et al. 2006

Neuropsychopharmacol

View full text Add to dashboard Cite

The atypical antipsychotic drug olanzapine increases body weight and visceral adiposity in schizophrenia. In rats, aging-associated increased body weight and visceral adiposity are reversed by administration of the pineal hormone melatonin. We asked if melatonin similarly would reverse olanzapine-induced increased weight and visceral adiposity in rats. Four groups (n ¼ 11/group) of female rats (240-250 g) were treated for 8 weeks with olanzapine, melatonin, olanzapine + melatonin, or vehicle alone in drinking water. Body weight and food and water consumption were determined weekly, locomotor activity at weeks 3 and 6, and nocturnal plasma melatonin concentration at week 7. At week 8, the rats were killed and visceral (perirenal, retroperitoneal, omental, and mesenteric) fat pads dissected and weighed. Olanzapine treatment reduced nocturnal plasma melatonin by 55% (po0.001), which was restored to control levels by olanzapine + melatonin. Body weight increased 18% in rats treated with olanzapine alone, but only 10% with olanzapine + melatonin, 5% with melatonin alone, and 7% with vehicle control. Body weight and visceral fat pad weight increases in rats treated with olanzapine alone were greater than in each of the other three groups (all po0.01), which were not significantly different. These results suggest that olanzapine-induced increases in body weight and visceral adiposity may be at least in part secondary to olanzapine-induced reduction of plasma melatonin levels, and that melatonin may be useful for the management of olanzapine-induced weight gain in humans.

show abstract

Section: Introductionmentioning

confidence: 99%

Olanzapine-Induced Weight Gain and Increased Visceral Adiposity is Blocked by Melatonin Replacement Therapy in Rats

Raskind

Burke

Crites

et al. 2006

Neuropsychopharmacol

View full text Add to dashboard Cite

show abstract

“…Par exemple, des résultats positifs sont observés pour la nizatidine (Atmaca et al, 2003 ;Atmaca et al, 2004), la reboxetine (Poyurovsky et al, 2003), l'amantadine (Deberdt et al, 2005) et le topiramate (Ko et al, 2005). Par contre, des résultats contradictoires pour la sibutramine (Henderson et al, 2005 ;Weiden et al, 2003) et négatifs pour la famotidine (Poyurovsky et al, 2004) et la fluoxetine (Bustillo et al, 2003 ;Poyurovsky et al, 2002) sont observés. L'interprétation des résultats est limitée, puisque les études sont de courte durée et incluent de petits échantillons dans leurs analyses.…”

Section: Résumé De L'articleunclassified

“…L'interprétation des résultats est limitée, puisque les études sont de courte durée et incluent de petits échantillons dans leurs analyses. Généralement, de faibles pertes de poids sont rapportées, mais les évidences actuelles sont insuffisantes pour prioriser une approche pharmacologique en particulier (Henderson et al, 2005 ;Hester et Thrower, 2005 ;Schwartz et al, 2004). En résumé, il y a peu de données qui supportent l'utilisation générale de la pharmacologie o 1 dans le contrôle du poids chez les patients atteints de troubles psychiatriques sévères (Faulkner et Cohn, 2006).…”

Section: Résumé De L'articleunclassified

Efficacité des programmes de modifications des habitudes de vie pour la gestion de poids des personnes avec des troubles psychiatriques

Bélanger

Provencher

Shriqui

2013

smq

View full text Add to dashboard Cite

Un gain de poids significatif est associé à l’utilisation des antipsychotiques atypiques, des stabilisateurs de l’humeur et des antidépresseurs employés seuls ou en combinaison. Les personnes avec des troubles psychiatriques sont plus à risque de souffrir d’obésité et du syndrome métabolique que la population générale. Une approche prometteuse pour limiter les conséquences physiques et psychologiques du gain de poids est la modification des habitudes de vie. Nous avons révisé la littérature afin de détailler l’impact de ces programmes sur différentes mesures d’effet. Douze des dix-sept études recensées rapportent un impact significatif de leur programme sur le poids en comparaison des soins usuels généralement offerts aux personnes avec des troubles psychiatriques. L’importance de la mise en place de ces programmes pour les patients psychiatriques en externe est soulignée.Significant weight gain is common in patients with psychiatric disorders taking antipsychotics, mood stabilisers and/or antidepressants. Psychiatric patients are at a higher risk of suffering from obesity and from the metabolic syndrome than the general population. One promising alternative to limiting weight gain involves modifying lifestyle behaviors. We reviewed the literature on behavioral weight management programs for this clientele. Of the 17 identified studies, 12 reported a significant impact of the program on weight gain compared to usual care. The importance of offering weight management programs to psychiatric patients in outpatient settings is stressed

show abstract

“…Se ha ensayado el uso de otros medicamentos asociados con el objeto de disminuir estos efectos secundarios, tales como sibutramina, fármaco indicado para manejo de obesidad el cual produce una disminución del apetito y aumento del gasto calórico basal 57 topiramato, droga antiepiléptica con capacidad de disminuir los atracones 58,59 y metformina, sensibilizador a la insulina que disminuye la resistencia a la insulina y el riesgo de diabetes 60 . Estos medicamentos se han usado con resultados positivos, aunque moderados.…”

Section: Enfoque Terapéuticounclassified

Alteraciones metabólicas asociadas al uso de terapia antipsicótica

A²,

et al. 2009

Rev. méd. Chile

View full text Add to dashboard Cite

show abstract

A Double-Blind, Placebo-Controlled Trial of Sibutramine for Olanzapine-Associated Weight Gain

Abstract: Sibutramine was an effective and well-tolerated adjunct to behavior modification for weight loss in patients with schizophrenia and schizoaffective disorder being treated with olanzapine.

Cited by 116 publications

References 36 publications

Olanzapine-Induced Weight Gain and Increased Visceral Adiposity is Blocked by Melatonin Replacement Therapy in Rats

Olanzapine-Induced Weight Gain and Increased Visceral Adiposity is Blocked by Melatonin Replacement Therapy in Rats

Efficacité des programmes de modifications des habitudes de vie pour la gestion de poids des personnes avec des troubles psychiatriques

Alteraciones metabólicas asociadas al uso de terapia antipsicótica

Contact Info

Product

Resources

About